



FOR IMMEDIATE RELEASE

Alder BioPharmaceuticals Announces Commencement of Follow-On Offering

BOTHELL, Wash., January 5, 2015 – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company, announced today that it has commenced a public offering of 4,000,000 shares of its common stock. Alder is offering all of the shares of common stock. In addition, Alder expects to grant the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the public offering price.

Credit Suisse, Leerink Partners and Wells Fargo Securities are acting as joint book-running managers for the offering. Sanford C. Bernstein is acting as co-manager for the offering.

The offering is being made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York, 10010, and by phone at 1-800-221-1037 or by email at newyork.prospectus@credit-suisse.com; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, and by phone at 1-800-808-7525 or by email at syndicate@leerink.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, or by email at cmclientsupport@wellsfargo.com, or by phone at 1-800-326-5897.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contacts:

David Schull or Andrea Flynn, Ph.D.
Russo Partners
(212) 845-4271
(646) 942-5631
david.schull@russopartnersllc.com
andrea.flynn@russopartnersllc.com

Investor Relations Contacts:

Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com